Treprostinil

Treprostinil
Clinical data
Trade namesRemodulin, Orenitram, Tyvaso, others
AHFS/Drugs.comMonograph
MedlinePlusa622038
License data
Pregnancy
category
  • AU: B3
Routes of
administration
Subcutaneous, intravenous, inhalation, by mouth
ATC code
Legal status
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability~100%
MetabolismSubstantially metabolized by the liver
Elimination half-life4 hours
ExcretionUrine (79% of administered dose is excreted as 4% unchanged drug and 64% as identified metabolites); feces (13%)
Identifiers
  • (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-Hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.236.149 Edit this at Wikidata
Chemical and physical data
FormulaC23H34O5
Molar mass390.520 g·mol−1
  • InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1 checkY
  • Key:PAJMKGZZBBTTOY-ZFORQUDYSA-N checkY
 X markNcheckY (what is this?)  (verify)

Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation among others, is a vasodilator that is used for the treatment of pulmonary arterial hypertension.

Treprostinil was approved for use in the United States in May 2002.

Medical uses

Treprostinil is indicated for the treatment of pulmonary arterial hypertension in people with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.

Treprostinil inhalation solution and treprostinil inhalation powder are indicated for the treatment of people with pulmonary arterial hypertension (WHO Group 1) to improve exercise ability; and people with pulmonary hypertension associated with interstitial lung disease (WHO Group 3) to improve exercise ability.

In the European Union, treprostinil (Trepulmix) is indicated for the treatment of adults with WHO Functional Class III or IV and inoperable chronic thromboembolic pulmonary hypertension; or persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment to improve exercise capacity.

Adverse effects

Common side effects depending on route of administration:

History

In 1976, the first paper on prostacyclin was published.

Treprostinil (Remodulin) was approved for medical use in the United States in May 2002, and again in July 2018.

Treprostinil (Tyvaso), as inhalation solution, was approved for medical use in the United States in July 2009, and again in April 2021.

Treprostinil (Orenitram), as extended release tablets, was approved for medical use in the United States in December 2013.

Treprostinil (Trepulmix) was authorized for medical use in the European Union in April 2020. Trepulmix is a hybrid medicine that is similar to the reference medicine Remodulin. It contains the same active substance, but it is used for treating a different form of pulmonary hypertension.

Treprostinil (Tyvaso DPI), as inhalation powder, was approved for medical use in the United States in May 2022.

Treprostinil (Yutrepia), as inhalation powder, was approved for medical use in the United States in June 2025.

Research

Treprostinil therapy may be effective in treating Degos disease.